Mechanistic studies uncover dual suppressive effects on GTP-RhoA and GTP-RAS by BET inhibitors, whereas the expression of a GTPase-regulating protein is found to be of clinical significance in a cohort of DLBCL patients. The gene discussed is RHOA; the disease is diffuse large B-cell lymphoma.